EA201990289A1 - АНТИТЕЛА К TGFβ, СПОСОБЫ И ПРИМЕНЕНИЯ - Google Patents

АНТИТЕЛА К TGFβ, СПОСОБЫ И ПРИМЕНЕНИЯ

Info

Publication number
EA201990289A1
EA201990289A1 EA201990289A EA201990289A EA201990289A1 EA 201990289 A1 EA201990289 A1 EA 201990289A1 EA 201990289 A EA201990289 A EA 201990289A EA 201990289 A EA201990289 A EA 201990289A EA 201990289 A1 EA201990289 A1 EA 201990289A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protgfβ1
garp
complex
antibodies
antigen
Prior art date
Application number
EA201990289A
Other languages
English (en)
Inventor
Грегори Дж. Карвен
Томас Шурпф
Кэтрин Тернер
Original Assignee
Сколар Рок, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сколар Рок, Инк. filed Critical Сколар Рок, Инк.
Priority claimed from PCT/US2017/042162 external-priority patent/WO2018013939A1/en
Publication of EA201990289A1 publication Critical patent/EA201990289A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Антитела, селективные к комплексу ProTGFβ1-GARP, полинуклеотиды, способные кодировать антитела, селективные к комплексу proTGFβ1-GARP, или антигенсвязывающие фрагменты, клетки, экспрессирующие антитела, селективные к комплексу proTGFβ1-GARP, или антигенсвязывающие фрагменты, а также ассоциированные векторы и меченные с возможностью обнаружения антитела, селективные к комплексу proTGFβ1-GARP, или антигенсвязывающие фрагменты могут быть использованы для усиления иммунного ответа у субъекта, например, против рака.
EA201990289A 2016-08-05 2017-07-14 АНТИТЕЛА К TGFβ, СПОСОБЫ И ПРИМЕНЕНИЯ EA201990289A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371355P 2016-08-05 2016-08-05
PCT/US2017/042162 WO2018013939A1 (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Publications (1)

Publication Number Publication Date
EA201990289A1 true EA201990289A1 (ru) 2019-06-28

Family

ID=66998669

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990289A EA201990289A1 (ru) 2016-08-05 2017-07-14 АНТИТЕЛА К TGFβ, СПОСОБЫ И ПРИМЕНЕНИЯ

Country Status (1)

Country Link
EA (1) EA201990289A1 (ru)

Similar Documents

Publication Publication Date Title
MX2019000514A (es) Anticuerpos de tgfb, métodos, y usos.
EA201892193A1 (ru) Химерные рецепторы к flt3 и способы их применения
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
MY200602A (en) Antibodies against tim3 and uses thereof
PH12018501902A1 (en) Gitr antibodies, methods, and uses
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2017008978A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
CR20170079A (es) Agentes de unión a cd123 y usos de estos
EA201400875A1 (ru) Антитела к cd47 и способы их применения
AR106555A1 (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
PE20170665A1 (es) Anticuerpos anti-tau humanizados
TR201903074T4 (tr) Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler.
EA201501063A1 (ru) СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CR20150575A (es) Anticuerpos humanos pac1
MX2015012540A (es) Ratón de cadena ligera común.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
MX2016011809A (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
WO2016023898A3 (en) Intracellular antigen binding
DK3455261T3 (da) Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf
EA201792058A1 (ru) Виротерапия комбинацией антител
EA201890739A1 (ru) Анти-s100a8 для лечения лейкемии